Nintedanib: A Review of Its Use as Second-Line Treatment in Adults with Advanced Non-Small Cell Lung Cancer of Adenocarcinoma Histology

Analysis of patient-reported outcomes from the LUME-Lung 1 trial: A randomised, double-blind, placebo-controlled, Phase III study of second-line nintedanib in patients with advanced non-small cell lung cancer

(2015) Silvia Novello et al.   EUROPEAN JOURNAL OF CANCER

Nintedanib plus docetaxel as second-line therapy in patients with non-small-cell lung cancer: a network meta-analysis

(2015) Sanjay Popat et al.   Future Oncology

Tolerability of Nintedanib (BIBF 1120) in Combination with Docetaxel: A Phase 1 Study in Japanese Patients with Previously Treated Non–Small-Cell Lung Cancer

(2015) Isamu Okamoto et al.   Journal of Thoracic Oncology

Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2014) M. Reck et al.   ANNALS OF ONCOLOGY

Phase I clinical trial of nintedanib plus paclitaxel in early HER-2-negative breast cancer (CNIO-BR-01-2010/GEICAM-2010-10 study)

(2014) M Quintela-Fandino et al.   BRITISH JOURNAL OF CANCER

Novel drugs against non-small-cell lung cancer

(2014) Robert Pirker   CURRENT OPINION IN ONCOLOGY

Bevacizumab: A Review of Its Use in Advanced Cancer

(2014) Gillian M. Keating   DRUGS

Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial

(2014) Martin Reck et al.   LANCET ONCOLOGY

Nintedanib for the treatment of patients with advanced non-small-cell lung cancer

(2014) Martin Reck et al.   Expert Review of Clinical Pharmacology

Effect of small angiokinase inhibitor nintedanib (BIBF 1120) on QT interval in patients with previously untreated, advanced renal cell cancer in an open-label, phase II study

(2013) Tim Eisen et al.   INVESTIGATIONAL NEW DRUGS

BIBF 1120 (Nintedanib), a Triple Angiokinase Inhibitor, Induces Hypoxia but not EMT and Blocks Progression of Preclinical Models of Lung and Pancreatic Cancer

(2013) B. Kutluk Cenik et al.   MOLECULAR CANCER THERAPEUTICS

Second-Line Therapy for Advanced NSCLC

(2013) J. M. Weiss et al.   ONCOLOGIST

A phase I, open-label dose-escalation study of continuous treatment with BIBF 1120 in combination with paclitaxel and carboplatin as first-line treatment in patients with advanced non-small-cell lung cancer

(2012) R. C. Doebele et al.   ANNALS OF ONCOLOGY

A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancer

(2011) M. Reck et al.   ANNALS OF ONCOLOGY

Randomized Phase II Placebo-Controlled Trial of Maintenance Therapy Using the Oral Triple Angiokinase Inhibitor BIBF 1120 After Chemotherapy for Relapsed Ovarian Cancer

(2011) Jonathan A. Ledermann et al.   JOURNAL OF CLINICAL ONCOLOGY

Pharmacokinetics and metabolism of BIBF 1120 after oral dosing to healthy male volunteers

(2011) Peter Stopfer et al.   XENOBIOTICA

Rationale for targeting VEGF, FGF, and PDGF for the treatment of NSCLC

(2011) Ballas et al.   OncoTargets and Therapy

Effect of BIBF 1120 on reversal of ABCB1-mediated multidrug resistance

(2011) Qing-feng Xiang et al.   CELLULAR ONCOLOGY

New antiangiogenics in non-small cell lung cancer treatment: Vargatef™ (BIBF 1120) and beyond

(2011) Bruno Gori et al.   Therapeutics and Clinical Risk Management

Phase I Open-Label Study of Continuous Treatment with BIBF 1120, a Triple Angiokinase Inhibitor, and Pemetrexed in Pretreated Non-Small Cell Lung Cancer Patients

(2010) P. M. Ellis et al.   CLINICAL CANCER RESEARCH

Phase I Safety, Pharmacokinetic, and Biomarker Study of BIBF 1120, an Oral Triple Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors

(2010) I. Okamoto et al.   MOLECULAR CANCER THERAPEUTICS

Phase I Study of the Angiogenesis Inhibitor BIBF 1120 in Patients with Advanced Solid Tumors

(2009) K. Mross et al.   CLINICAL CANCER RESEARCH

Design, Synthesis, and Evaluation of Indolinones as Triple Angiokinase Inhibitors and the Discovery of a Highly Specific 6-Methoxycarbonyl-Substituted Indolinone (BIBF 1120)

(2009) Gerald J. Roth et al.   JOURNAL OF MEDICINAL CHEMISTRY

BIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy

(2008) F. Hilberg et al.   CANCER RESEARCH